RegeneRx Biopharmaceuticals Inc is a company that values innovation, integrity, and commitment to improving human health. With a strong corporate philosophy centered on research and development, RegeneRx strives to develop groundbreaking therapeutics and cutting-edge products in the field of tissue regeneration. The company's dedication to scientific advancement and its relentless pursuit of novel drug candidates make RegeneRx a prominent player in the biopharmaceutical industry. By prioritizing patient well-being and fostering partnerships with healthcare professionals, RegeneRx Biopharmaceuticals Inc continues to pave the way for new and effective treatments, setting the bar high for the industry.

RegeneRx Biopharmaceuticals Inc is primarily present in the United States. However, the company's presence extends globally with strategic collaborations and partnerships that allow them to conduct research and clinical trials in various countries and regions. These collaborations serve to accelerate the development and commercialization of their innovative therapeutic candidates. RegeneRx actively focuses on advancing their pipeline of potential treatments for ophthalmic, dermatologic, and cardiovascular conditions, ensuring their reach and impact are felt by patients worldwide.

RegeneRx Biopharmaceuticals Inc has achieved several significant milestones in its history. One of the major achievements is the successful completion of clinical trials for their drug candidate, TB4, in treating various medical conditions. The company has also received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase III clinical trials for the treatment of dry eye syndrome. Additionally, RegeneRx has secured partnerships and collaborations with leading pharmaceutical companies for further development and commercialization of their products. These milestones demonstrate the company's commitment to advancing innovative therapies and expanding its presence in the biopharmaceutical industry.

RegeneRx Biopharmaceuticals Inc is a renowned biopharmaceutical company with a rich history and notable background. Founded in 1982, RegeneRx focuses on the discovery and development of innovative therapeutic peptides. With a dedicated commitment to advancing novel treatments, the company specializes in tissue healing and repair through its unique drug development platform. RegeneRx's most prominent product is Thymosin Beta 4, a synthetic copy of a naturally occurring regenerative protein. This powerful peptide has shown promising results in various clinical studies for a wide range of injuries and diseases. RegeneRx Biopharmaceuticals Inc is continuously striving to make a significant impact in the field of regenerative medicine.

The main competitors of RegeneRx Biopharmaceuticals Inc in the market include companies such as Novartis AG, Amgen Inc, Pfizer Inc, Johnson & Johnson, and Genentech Inc.

RegeneRx Biopharmaceuticals Inc is primarily active in the biopharmaceutical industry.

RegeneRx Biopharmaceuticals Inc. is a leading biopharmaceutical company. The company's business model revolves around developing innovative therapeutic products to address unmet medical needs. RegeneRx focuses on the research and development of peptide-based drugs that promote tissue and organ repair. With a strong pipeline of drug candidates, the company aims to provide effective solutions for various diseases and conditions, including ophthalmological disorders, dermatological conditions, and cardiovascular diseases. Through strategic partnerships and collaborations, RegeneRx aims to bring its cutting-edge therapies to the market, ultimately improving patients' lives and delivering value to its shareholders.

De K/W-verhouding kan momenteel niet worden berekend voor RegeneRx Biopharmaceuticals.

De KUV kan momenteel niet worden berekend voor RegeneRx Biopharmaceuticals.

De AlleAktien Kwaliteitsscore voor RegeneRx Biopharmaceuticals is 4/10.

De omzet kan momenteel niet worden berekend voor RegeneRx Biopharmaceuticals.

De winst kan momenteel niet berekend worden voor RegeneRx Biopharmaceuticals.

RegeneRx Biopharmaceuticals Inc. is a US biotechnology company focused on developing and marketing drugs and therapies for the treatment of eye disorders, skin disorders, and neurological disorders. The company has a wide portfolio of patented therapeutic agents developed based on peptides from the thymosin family. Their business model is based on collaborating with research institutions and regulatory authorities around the world to develop and bring novel and effective therapies to market. They have a strong focus on science and research to understand the fundamental issues of human tissue regeneration and develop innovative therapies. One of their key areas is the development of eye therapies. They have developed a highly effective drug called RGN-259 for the treatment of dry eye and other eye disorders. The drug contains Thymosin Beta-4, a peptide molecule that promotes tissue regeneration at a cellular level and can reduce inflammation levels. They are also focused on developing therapeutic injections and ointments for treating skin disorders, with an FDA approval for RGN-137, a topical ointment for treating hemorrhoids. In addition, they are working on novel therapies for dermatitis, psoriasis, and burns. In the field of neurological medicine, they are working on developing drugs for Alzheimer's and Parkinson's diseases, collaborating with leading neurological research institutions to study the impact of their peptide therapies on the nervous system. Overall, RegeneRx Biopharmaceuticals' business model is centered around the development and marketing of novel therapies and drugs based on thymosin family peptides for the treatment of eye disorders, skin disorders, and neurological disorders. They collaborate with research institutions and regulatory authorities to validate and refine their treatment protocols and maximize their market opportunities.

RegeneRx Biopharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor RegeneRx Biopharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van RegeneRx Biopharmaceuticals is US75886X1081.

Het WKN van RegeneRx Biopharmaceuticals is 875295.

De ticker van RegeneRx Biopharmaceuticals is RGRX.

Binnen de laatste 12 maanden betaalde RegeneRx Biopharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal RegeneRx Biopharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van RegeneRx Biopharmaceuticals is momenteel .

RegeneRx Biopharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

RegeneRx Biopharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

RegeneRx Biopharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van RegeneRx Biopharmaceuticals van 7-10-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 7-10-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 7-10-2024.

In het jaar 2023 heeft RegeneRx Biopharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van RegeneRx Biopharmaceuticals worden in USD uitgekeerd.